Skip to main content Skip to main menu
UF Health University of Florida
Department of Urology College of Medicine – Jacksonville
Request an Appointment
Mark G Bandyk

Mark G Bandyk, MD, MPH, MS

Professor, University of Florida

Department: Urology – Jacksonville
Business Phone: (904) 383-1016
Business Email: mark.bandyk@jax.ufl.edu

On This Page

About Mark G Bandyk

Mark Bandyk, M.D., M.P.H., M.S., is a University of Florida professor of urology and a board-certified urologist at UF Health Jacksonville. He received his medical degree from George Washington University in Washington, DC. He completed a tumor immunology fellowship at the Salk Institute in La Jolla, California, and his residency in urology at Columbia University in New York, New York. Dr. Bandyk also completed a urologic oncology fellowship at the University of Texas in Houston. Dr. Bandyk is a urologic oncologist with a special interest in bladder and renal cancer. He is an expert in robotic and open surgery.

Additional Positions:
Professor
2025 – Current · University of Florida
Associate Professor
2016 – 2025 · University of Florida

Board Certifications

  • Urology
    American Board of Urology

Clinical Profile

Specialties

  • Urology

Research Profile

Areas of Interest

  • urothelial carcinoma

Publications

Academic Articles

Grants

  1. A PhAse 1b/2, Dose expansion, open-label study to eValuate sAfety and anti-tumor activity, of iNtravesiCal instillation of TARA-002 in adults with high-gradE non-muscle invasive blaDder cancer

    Active

    Role:
    Principal Investigator
    Funding:
    PROTARA THERAPEUTICS

  2. Long-Term Prospective Registry to Evaluate Treatment Decisions and Clinical Outcomes in Prostate Cancer Patients from Diverse Urology Practice Settings following Prolaris Testing

    Role:
    Principal Investigator
    Funding:
    MYRIAD GENETICS

  3. A Phase 3, Multinational, Randomized, Open-Label, Three Parallel-Arm Study of PF-06801591, an anti-PD-1 antibody, in Combination with Bacillus Calmette-Guerin (BCG Induction With or Without BCG Maintenance) Versus BCG (Induction and Maintenance) in Participants with High-Risk, BCG Na?ve Non-Muscle Invasive Bladder Cancer

    Active

    Role:
    Principal Investigator
    Funding:
    ICON CLINICAL RESEARCH INC via PFIZER INC

  4. A Phase 2 Study of BC-819 in Patients with Non-Muscle Invasive Bladder Cancer Whose Disease is Unresponsive to Bacillus Calmette-Guerin

    Role:
    Principal Investigator
    Funding:
    SYNEOS HEALTH via ANCHIANO THERAPEUTICS

Education

  1. Urologic Oncology Fellowship

    University of Texas

  2. Urology Residency

    Columbia University

  3. Surgery Residency

    University of California San Francisco School of Medicine

  4. Tumor Immunology Fellow

    Salk Institute

  5. Doctor of Medicine

    George Washington University

Contact Details

Phones:
Business:
(904) 383-1016
Emails:
Business:
mark.bandyk@jax.ufl.edu
Addresses:
Business Mailing:
653 W 8TH ST
 JACKSONVILLE FL 32209
Business Street:
653 W 8TH ST
 JACKSONVILLE FL 32209